长春高新：关于子公司GenSci134注射液境内生产药品注册临床试验申请获得批准的公告

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of GenSci134 injection, marking a significant step in the company's drug development process [2] Company Summary - The approval pertains to the domestic production drug registration clinical trial application for GenSci134 injection, indicating progress in the company's research and development efforts [2]